Breaking News, Promotions & Moves

IsomAb Appoints Dr. Philip Brainin as Chief Executive Officer

Brainin brings a combination of cardiovascular medicine, clinical research, and venture investing experience across EU and U.S. biotechnology companies.

Author Image

By: Charlie Sternberg

Associate Editor

IsomAb Ltd, a UK-based biotechnology company, has appointed Dr. Philip Brainin as Chief Executive Officer (CEO) and member of the Board of Directors. Brainin is tasked with taking lead candidate ISM-001 for chronic stable angina (CSA) into clinical development. ISM-001’s preclinical data showing complete restoration of blood flow in severe ischemic disease models supports the company’s stated goal of delivering a disease-modifying treatment for chronic stable angina (CSA), a condi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters